A Clinical Trial to Compare Etrolizumab with Infliximab in Patients with Moderate to Severe Ulcerative Colitis Who Have not Received Treatment with Tumour Necrosis Factor Inhibitors (Gardenia)

Phase III, randomized, multicenter double-blind, double dummy study to evaluate the efficacy and safety of Etrolizumab compared with Infliximab in patients with moderate to severe active Ulcerative Colitis who are naïve to TNF inhibitors

  • Autoimmune Disorder
  • Inflammatory Bowel Disease (IBD)
  • Ulcerative Colitis
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Completed

This study runs in
Cities
  • Alcorcón
  • Amsterdam
  • Ansan-si
  • Antwerpen
  • Barcelona
  • Berlin
  • Bern
  • Bloemfontein
  • Bonheiden
  • Bournemouth
  • Braga
  • Bruxelles
  • București
  • Budapest
  • bury
  • Busan
  • Békéscsaba
  • Caen
  • Calgary
  • Cambridge
  • Cape Town
  • cascina-perseghetto
  • Chambray-lès-Tours
  • Clermont-Ferrand
  • Clichy
  • Coventry
  • Creixomil
  • Daegu
  • Debrecen
  • Edmonton
  • Eger
  • Exeter
  • Ferrol
  • Firenze
  • Freiburg im Breisgau
  • Gent
  • Guelph
  • Győr
  • Hamburg
  • Herentals
  • Hlavní město Praha
  • Jette
  • Jihomoravský kraj
  • Kiel
  • Kladno
  • Královéhradecký kraj
  • Köln
  • Leeds
  • London
  • Longueuil
  • Maastricht
  • Madrid
  • Milano
  • Miskolc
  • Montpellier
  • Montréal
  • Newcastle upon Tyne
  • Nice
  • Nijmegen
  • nordbyhagen
  • Nottingham
  • Ostrava
  • oullins-pierre-benite
  • Padova
  • Pardubice
  • Parma
  • Petah Tikva
  • Pisa
  • Roma
  • Sabadell
  • Salzburg
  • San Donato Milanese
  • San Giovanni Rotondo
  • Saskatoon
  • Seongnam-si
  • Seoul
  • Singapore
  • Southampton
  • Stockholms län
  • Suwon-si
  • Szeged
  • Székesfehérvár
  • Tel Aviv District
  • Timișoara
  • Torino
  • Târgu Mureș
  • València
  • Vandœuvre-lès-Nancy
  • Wonju-si
  • zlin-1
  • Zürich
  • Ústecký kraj
Study Identifier:

NCT02136069 2013-004282-14 GA29103

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to severe ulcerative colitis (UC) who are naive to tumor necrosis factor (TNF) inhibitors. Participants will be randomized in a 1:1 ratio to receive either etrolizumab 105 milligrams (mg) by subcutaneous (SC) injection once every 4 weeks (Q4W) + placebo (intravenous [IV] infusion at Weeks 0, 2, and 6, then once every 8 weeks [Q8W]) or infliximab 5 milligrams/kilogram (mg/kg) IV at Weeks 0, 2, and 6, then Q8W) + placebo (SC Q4W). Time on treatment is 54 weeks.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02136069, GA29103, 2013-004282-14 Study Identifier
      etrolizumab, infliximab, placebo (IV), placebo (injection) Treatments
      Ulcerative Colitis Condition
      Official Title

      Phase III, Randomized, Multicenter Double-Blind, Double Dummy Study to Evaluate the Efficacy and Safety of Etrolizumab Compared With Infliximab in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors

      Eligibility Criteria

      All Gender
      ≥ 18 Years & ≤ 80 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Moderately to severely active UC as determined by the Mayo Clinic Score assessment (MCS)
      • Naive to treatment with any anti-TNF inhibitor therapy (including TNF inhibitor biosimilars)
      • An inadequate response to or intolerance of prior corticosteroid and/or immunosuppressant treatment
      • Background regimen for UC may include oral 5-aminosalicylate (5-ASA), oral corticosteroids, budenoside multi-matrix system (MMX), probiotics, azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX) if doses have been stable during the screening period
      • Use of highly effective contraception during and at least 24 weeks after the last dose of study drug
      Exclusion Criteria
      • A history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic, radiation or microscopic colitis, Crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps
      • Prior or planned surgery for UC
      • Past or present ileostomy or colostomy
      • Have received non-permitted inflammatory bowel disease (IBD) therapies (including natalizumab, vedolizumab, efalizumab, and tofactinib)
      • History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, human, or humanized antibodies; fusion proteins, or murine proteins; hypersensitivity to etrolizumab or any of its excipients
      • Chronic hepatitis B or C infection, Human deficiency virus (HIV) or tuberculosis (active or latent)

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other studies on ForPatients in related disease areas.

      Ulcerative Colitis

      Clinical Research Explained

      Information about what clinical studies and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now